What Avalyn Pharma Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 4 |
| Sells | 4 | 4 |
| Total trades | 4 | 21 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 9,055,232 |
| Disposed | 228,454 | 228,454 |
| Net activity | −228,454 | +8,826,778 |
Common stock only — 2 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Fmr Llc | 10% owner | Nov 10 | Open-market sale · S | −47,889 | $30.28 | −$1.45M | 2,056,081 |
| Fmr Llc | 10% owner | Nov 10 | Open-market sale · S | −5,565 | $29.56 | −$165K | 2,103,970 |
| Fmr Llc | 10% owner | Nov 09 | Open-market sale · S | −1,339 | $29.75 | −$39.8K | 2,109,535 |
| Fmr Llc | 10% owner | Nov 09 | Open-market sale · S | −173,661 | $29.06 | −$5.05M | 2,110,874 |
| Fmr Llc | 10% owner | May 01 | Derivative Conversion · C | +377,948 | — | — | 2,284,535 |
| Fmr Llc | 10% owner | May 01 | Derivative Conversion · C | +225,843 | — | — | 1,906,587 |
| Fmr Llc | 10% owner | May 01 | Derivative Conversion · C | +872,868 | — | — | 1,680,744 |
| Fmr Llc | 10% owner | May 01 | Derivative Conversion · C | +80,291 | — | — | 807,876 |
| Fmr Llc | 10% owner | May 01 | Derivative Conversion · C | +727,585 | — | — | 727,585 |
| Sr One Capital MANAGEMENT, Llc | 10% owner | May 01 | Open-market buy · P | +277,777 | $18.00 | +$5M | 1,122,087 |
| Sr One Capital MANAGEMENT, Llc | 10% owner | May 01 | Derivative Conversion · C | +489,486 | — | — | 844,310 |
| Sr One Capital MANAGEMENT, Llc | 10% owner | May 01 | Derivative Conversion · C | +354,824 | — | — | 354,824 |
| Sr One Capital MANAGEMENT, Llc | 10% owner | May 01 | Open-market buy · P | +277,778 | $18.00 | +$5M | 2,186,562 |
| Sr One Capital MANAGEMENT, Llc | 10% owner | May 01 | Derivative Conversion · C | +489,486 | — | — | 1,908,784 |
| Sr One Capital MANAGEMENT, Llc | 10% owner | May 01 | Derivative Conversion · C | +1,419,298 | — | — | 1,419,298 |
| Wellington Biomedical Innovation Master Investors (Cayman) Ii L.p. | 10% owner | May 01 | Derivative Conversion · C | +1,275,486 | — | — | 1,275,486 |
| Carroll Jill | Director | May 01 | Open-market buy · P | +277,778 | $18.00 | +$5M | 2,186,562 |
| Carroll Jill | Director | May 01 | Derivative Conversion · C | +489,486 | — | — | 1,908,784 |
| Carroll Jill | Director | May 01 | Derivative Conversion · C | +1,419,298 | — | — | 1,419,298 |
| Novo Holdings A/S | 10% owner | May 01 | Open-market buy · P | +555,555 | $18.00 | +$10M | 3,883,289 |
Loading...